ASP0739
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ASP0739, covering 2024-08-06 to 2024-08-06. Get the full timeline:
Most recent: Clinical Trial Update: Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants [Phase 1, Phase 2]